CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Abstract

In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2, no specific and effective drugs for treating this disease have been reported until today. Angiotensin-converting enzyme 2 (ACE2), a receptor of SARS-CoV-2, mediates the virus infection by binding to spike protein. Although ACE2 is expressed in the lung, kidney, and intestine, its expressing levels are rather low, especially in the lung. Considering the great infectivity of COVID-19, we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection. Here, we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein. The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody, Meplazumab, inhibits SARS-CoV-2 amplification. Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells, which can be neutralized by CD147 extracellular fragment. Viral loads are detectable in the lungs of human CD147 (hCD147) mice infected with SARS-CoV-2, but not in those of virus-infected wild type mice. Interestingly, virions are observed in lymphocytes of lung tissue from a COVID-19 patient. Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dose-dependent manner, which is specifically inhibited by Meplazumab. Furthermore, CD147 mediates virus entering host cells by endocytosis. Together, our study reveals a novel virus entry route, CD147-spike protein, which provides an important target for developing specific and effective drug against COVID-19.

Cited by papers we hold 41

• Human SARS-CoV-2 challenge uncovers local and systemic response dynamics · 2024
  Corrected
• Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. · 2022
  Not checked
• Emerging Insights on Caspases in COVID-19 Pathogenesis, Sequelae, and Directed Therapies · 2022
  Not checked
• Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review · 2022
  Not checked
• Pan-Cancer Analysis, Reveals COVID-19-Related BSG as a Novel Marker for Treatment and Identification of Multiple Human Cancers · 2022
  Not checked
• Tropism of SARS-CoV-2 for human cortical astrocytes · 2022
  Corrected
• SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
  No notice
• SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
  No notice
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• Gender and genetic factors impacting COVID-19 severity · 2021
  Not checked
• SARS-CoV-2–associated ssRNAs activate inflammation and immunity via TLR7/8 · 2021
  No notice
• Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis · 2021
  Not checked
• A cohort autopsy study defines COVID-19 systemic pathogenesis · 2021
  No notice
• Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy · 2021
  No notice
• Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection · 2021
  Not checked
• Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. · 2021
  Not checked
• SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism · 2021
  Not checked
• The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease · 2021
  Corrected
• SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro · 2021
  No notice
• The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells · 2021
  No notice

and 21 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.